FDA proposal to drop adequate provision could effectively ban prescription drug ads

FDA staff are proposing to eliminate the adequate provision requirement in direct-to-consumer prescription-drug advertisements. The adequate provision currently obliges advertisers to present a balanced view of a drug’s benefits and risks in a clear and understandable way.

Experts warn that without this requirement, companies would have to disclose the full safety profile in every ad, which would dramatically raise production costs and make broadcast advertising impractical. The added expense could effectively shut down most prescription-drug advertising.

The loss of the adequate provision could also make ads harder for patients to comprehend, reducing the usefulness of the information presented. Industry observers see the change as a significant regulatory shift that may reshape how drugs are marketed to the public.